Pasithea Therapeutics Corp.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KTTA research report →
Range $3 – $3
Price Chart
About the company
Pasithea Therapeutics Corp. functions as a biotechnology firm dedicated to the discovery and advancement of novel therapeutic solutions for various psychiatric and neurological conditions. Beyond its research endeavors, the company also plans to establish and manage clinics specializing in depression treatment.
- CEO
- Tiago Reis Marques
- IPO
- 2021
- Employees
- 5
- HQ
- Miami Beach, FL, US
Get TickerSpark's AI analysis on KTTA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $17.59M
- P/E
- -0.16
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- 1515.54
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -0.23%
- ROIC
- -0.06%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-20,857,295
- Net Income
- $-20,427,683-46.9%
- EPS
- $-2.91+77.1%
- OCF Growth
- -9.3%
- FCF Growth
- -9.3%
- 52W High
- $2.06
- 52W Low
- $0.28
- 50D MA
- $0.47
- 200D MA
- $0.61
- Beta
- 0.29
- RSI (14)
- 50
- Avg Volume
- 708.78K
No earnings-call transcripts are available for KTTA yet.
- Free Float
- 96.4%
- Shares Outstanding
- 36.75M
- Float Shares
- 35.43M
of shares held by institutions
24 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Cable Car Capital, LP | 3.00M | ▲ 1.79M |
| Stonepine Capital Management, LLC | 2.77M | ▲ 572.77K |
| Adage Capital Partners Gp, L.L.C. | 2.10M | 0 |
| Jupiter Topco LLC | 2.10M | ▲ 2.10M |
| Janus Henderson Group Ltd. | 2.10M | 0 |
| Opaleye Management Inc. | 2.05M | ▲ 2.05M |
| Ameriprise Financial Inc | 1.86M | ▲ 513.59K |
| Advisorshares Investments LLC | 1.16M | ▲ 222.50K |
| Squadron Capital Management LLC | 1.00M | ▼ 1.10M |
| Vivo Capital, LLC | 372.80K | ▼ 92.67K |
| Persistent Asset Partners Ltd | 290.56K | 0 |
| Geode Capital Management, LLC | 178.00K | ▲ 94.14K |
Held by 6 ETFs
Biggest fund positions in KTTA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 17, 26 | Coastlands Capital LP | buy | 875,000 |
| Nov 16, 26 | Coastlands Capital LP | buy | 583,083 |
| Nov 13, 26 | Coastlands Capital LP | buy | 209,431 |
| Jun 17, 26 | Coastlands Capital LP | buy | 100,000 |
| May 1, 26 | Marques Tiago | other | 1,756,069 |
| May 1, 26 | STEINMAN LAWRENCE | other | 152,783 |
| May 1, 26 | Dumesnil Simon | other | 152,783 |
| May 1, 26 | Schneiderman Daniel H | other | 1,129,323 |
| May 1, 26 | Krishnan Kartik | other | 1,129,323 |
| May 1, 26 | Leahy Emer | other | 152,783 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our KTTA coverage
Recent articles, reports, and earnings notes.
No research on KTTA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate KTTA report →Pasithea's PAS-004 Shrinks Skin Tumors in All 15 Evaluable Patients
benzinga.com · Nov 13
Pasithea Therapeutics Presents Positive Initial Phase 1/1b Data for PAS-004, Showing Substantial Reductions in Cutaneous Neurofibroma Size and Early Activity in Plexiform Neurofibromas at the 2026 European Neurofibromatosis Conference
globenewswire.com · Nov 13
Pasithea Therapeutics Announces FDA Clearance of IND for PAS-004 in Neurofibromatosis Type 1 (NF1)-Associated Cutaneous Neurofibromas (cNF)
globenewswire.com · Nov 3
Pasithea Therapeutics to Host Virtual KOL Event on NF1 Treatment November 4, 2026
globenewswire.com · Oct 28
Pasithea Therapeutics Announces Positive PAS-004 Clinical Data from Phase 1 Advanced Cancer Study Presented at ESMO Congress 2026
globenewswire.com · Oct 23
Pasithea Therapeutics (NASDAQ:KTTA) Shares Down 2.7% – Time to Sell?
defenseworld.net · Oct 4
Pasithea Therapeutics Announces Presentation of Initial PAS-004 Clinical Data from Ongoing Phase 1/1b Clinical Trial in Adult NF1 Patients at the 2026 European Neurofibromatosis Conference
globenewswire.com · Sep 14
Pasithea Therapeutics Announces Participation in Two September 2026 Investor Conferences
globenewswire.com · Sep 3
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.